Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

 Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

**The Biotech Giant Just Reminded Wall Street That It Was Never Just a Pandemic Story — And Investors Are Finally Listening**

---

## The Moment That Changed the Narrative

Let me tell you about a woman named Karen. She’s a portfolio manager at a mid-sized investment firm in Boston. She’s been watching Moderna for years. She remembers the pandemic days when the stock was flying high, and she remembers the crash that followed when the world moved on from Covid.

For most of 2024 and 2025, Karen couldn’t get her colleagues to take Moderna seriously. “It’s a one-trick pony,” they’d say. “Covid is over. What else do they have?”

She’d try to explain about the pipeline. About the mRNA platform. About the cancer vaccine. But nobody wanted to hear it. The stock was dead, and that was that.

Then August 19, 2026 happened. Moderna announced positive Phase 3 data for its personalized cancer vaccine, and the stock **nearly tripled in a single day**. Karen’s phone started ringing. Suddenly, everyone wanted to talk about Moderna.

And then this week, something even more interesting happened. On Wednesday, September 23, Moderna CEO Stéphane Bancel took the stage at Bernstein’s annual healthcare conference and said something that cut to the heart of the debate.

“Moderna has never been a Covid vaccine company,” he said. “We’re an mRNA platform company”.

The stock hit a **52-week high of $192.31** that day. It closed the week at **$194.82**, up nearly **7%** on Thursday alone. Year-to-date, the stock is up more than **500%**.

Karen was right. And now the rest of the market is playing catch-up.

---

## The Numbers: A Stock on Fire

Let’s get the raw data on the table, because the magnitude of this move is genuinely historic.

**The Price Action:**

Moderna shares closed Thursday, September 24, at **$194.82**, up **6.98%** for the day. The stock hit an intraday high of **$195.71** — a new 52-week high. The previous close was $182.11.

But the daily move is just the tip of the iceberg.

**The Longer-Term Picture:**

- **1-week return:** +25%

- **1-month return:** +31%

- **3-month return:** +205%

- **Year-to-date:** +517%

- **1-year return:** +606%

Over the past 52 weeks, Moderna has traded between a low of **$22.28** and a high of **$195.71**. That’s a range of nearly **800%**.

The stock now carries a **market capitalization of approximately $72.7 billion**.

**The Volume:**

Trading volume has been elevated, with **16.4 million shares** changing hands on Thursday alone — close to the three-month average of 16.7 million. On Wednesday, volume hit **17.7 million**, and on Monday, it was **21 million**. Investors are paying attention.

---

## Why This Is Happening: The Cancer Vaccine Story

To understand why Moderna is surging, you have to understand what happened in August.

On August 19, 2026, Moderna and its partner Merck announced that their personalized cancer vaccine, **intismeran autogene**, had achieved a major breakthrough in a Phase 3 trial. The study evaluated the vaccine in combination with Merck’s Keytruda as an adjuvant treatment for patients with resected melanoma — skin cancer that had been surgically removed but carried a high risk of recurrence.

The results showed that the combination **prevented cancer from returning more effectively than Keytruda alone**. The trial met both its primary endpoint and a secondary endpoint of distant metastasis-free survival at the first interim analysis.

This wasn’t a small trial. It involved approximately **1,100 patients** in a rigorously controlled, blinded study.

The stock reaction was explosive. Moderna shares **nearly tripled in a single session** — a move that made headlines across Wall Street.

“The Phase 3 results marked a major success for the field of personalized cancer vaccines,” noted Leerink Partners analyst Lili Nsongo, who added that previous failures in the field “paint a complex picture for mRNA cancer vaccines”.

What makes intismeran different is its **personalization**. The vaccine is engineered to flag dozens of mutations unique to each patient’s tumor. It’s not a one-size-fits-all treatment. It’s a custom-built therapy designed for each individual’s cancer.

“Moderna owns the proprietary work involved in selecting the 34 mutations included in each individualized cancer vaccine,” Bancel explained at the Bernstein conference. External partners provide DNA sequencing data, but Moderna handles the downstream analysis and selection process.

---

## Beyond Covid: The Platform Story

But here’s the thing that Bancel wants investors to understand: Covid was never the point. It was an opportunity. A validation. A proof of concept.

“Moderna has been an mRNA platform company since its founding,” Bancel said. The Covid vaccine was “an unplanned but necessary response to the pandemic rather than the company’s long-term strategy”.

The company now has **five approved products** and two product launches planned for this year. That’s up from zero in 2020.

**The Respiratory Vaccine Business**

Moderna’s commercial portfolio includes:

- **Spikevax** (Covid-19 vaccine), approved in 40 countries

- **mNEXSPIKE** (next-generation Covid vaccine), approved in the U.S. and Canada

- **mRESVIA** (RSV vaccine), approved in 40 countries

- **mRNA-1010** (seasonal flu vaccine), submissions completed in major markets

- **mRNA-1083** (flu + Covid combination vaccine), under review in Europe and Canada

The company expects growth from long-term partnerships in the UK, Canada, and Australia, and is targeting entry into the flu vaccine market in 2027. By 2028, Moderna anticipates a first-to-market flu/Covid combination vaccine and a potential norovirus vaccine, expanding its seasonal franchise to as many as **six approved products**.

**The Oncology Pipeline**

Intismeran is just the beginning.

Moderna has **eight Phase 2 and Phase 3 clinical trials underway** for the cancer vaccine across multiple tumor types, including melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

Chief Development Officer David Berman outlined the breadth of the program at the Bernstein conference. There are ongoing studies in:

- Lung cancer (three Phase 3 trials)

- Renal cell carcinoma

- Bladder cancer

- Pancreatic cancer

- Gastric cancer

The company is also studying intismeran in earlier stages of disease, including a Phase 3 trial in stage 1 lung cancer and a randomized Phase 2 trial in non-muscle-invasive bladder cancer.

Berman noted that Moderna’s view is that the treatment **may be active without a PD-1 inhibitor** — potentially creating opportunities in settings where checkpoint inhibitors are not commonly used.

**The Rare Disease Pipeline**

Beyond oncology, Moderna is advancing programs in rare genetic diseases. Bancel said the company expects **pivotal data for propionic acidemia by year-end**. He described the program as the first of what could become a broader liver-focused rare-disease franchise, using mRNA to direct the liver to produce missing or deficient proteins.

Moderna has published work involving more than **12 rare genetic liver-disease models** and intends to advance additional programs using the same delivery approach and manufacturing infrastructure.

---

## The Next Catalyst: ESMO Presentations

If you’re trying to understand what could drive the stock from here, mark your calendar for late October.

Moderna announced Monday that **three abstracts on intismeran autogene** have been accepted for presentation at the **European Society for Medical Oncology (ESMO) Congress 2026**, to be held October 23-27 in Madrid, Spain.

This is one of the largest oncology conferences in the world. And the presentations will provide the first full, detailed look at the data that caused the stock to nearly triple in August.

**The three presentations:**

1. **The flagship presentation:** Full Phase 3 results for intismeran autogene plus Keytruda as adjuvant treatment for resected melanoma. This is the data that started everything.

2. **Pancreatic cancer:** Early-stage trial results for the vaccine following Folfirinox, an aggressive chemotherapy regimen, in cancer confined to the small ducts in the pancreas.

3. **Lung cancer:** Phase 3 results showing the efficacy of intismeran autogene alongside immunotherapy in patients with early-stage non-small cell lung cancer.

“The highest-profile presentation will showcase the results of a Phase 3 trial evaluating a combination of intismeran autogene and Merck’s Keytruda,” Barron’s noted. “An early look at the data in August showed the combined treatment prevented cancer from returning more effectively than Keytruda alone”.

Investors should expect volatility around the event. The August data release caused a massive move. The full data could either confirm the enthusiasm or raise questions.

---

## The Partnership with Merck: A Strategic Alliance

Intismeran isn’t a solo effort. It’s being developed in partnership with **Merck**, one of the world’s largest pharmaceutical companies.

The collaboration dates back years. Merck paid **$200 million upfront** to kick off the project and another **$250 million in 2022**. Under the current agreement, the companies **share costs equally** — including commercial, clinical, manufacturing, and capital expenditures — with remaining profit **split evenly**.

For Merck, the partnership is strategic. Keytruda, its blockbuster immunotherapy, has been the world’s best-selling drug for roughly three years. But it faces **loss of exclusivity in 2028**. Merck has been scrambling to expand its pipeline and secure new indications for Keytruda.

Intismeran could be the answer. If approved, it would shift Keytruda “from a drug facing a patent cliff into the cornerstone of a personalized platform”.

For Moderna, the partnership provides validation, resources, and commercial reach. Merck’s oncology salesforce is one of the most experienced in the industry.

---

## The Manufacturing Challenge: Scaling Personalization

Here’s the thing about personalized cancer vaccines: they’re incredibly difficult to manufacture at scale.

Unlike traditional vaccines, which are produced in massive batches, intismeran is **custom-made for each patient**. The process involves:

1. Collecting a patient’s tumor sample

2. Sequencing the DNA to identify unique mutations

3. Selecting the 34 most promising targets

4. Manufacturing a custom mRNA vaccine

5. Shipping it back to the hospital for administration

This is complex. It’s time-sensitive. And it requires coordination between Moderna, Merck, hospitals, and patients.

Bancel acknowledged the challenge at the Bernstein conference. He said the **principal bottleneck may be hospital operations** rather than manufacturing — particularly the ability to rapidly obtain biopsies and related patient information.

“Moderna and Merck are establishing teams to support hospitals and standardize those processes,” Bancel said. The companies have built a **digital platform** to track operational steps while maintaining patient privacy.

Moderna has also built a **purpose-built facility in Marlborough, Massachusetts**, specifically for intismeran manufacturing. The site is “designed for speed and scalability with advanced automation and robotics,” and began clinical batch supply in September 2025.

Bancel described intismeran manufacturing as “a synthetic, cell-free liquid process that can be scaled through smaller equipment footprints and faster cycle times”.

---

## Frequently Asked Questions

**Q: What caused Moderna stock to hit a new high this week?**

A: CEO Stéphane Bancel told investors at the Bernstein healthcare conference that Moderna is “an mRNA platform company,” not just a Covid vaccine maker. He highlighted the company’s expansion into oncology and rare diseases, including its personalized cancer vaccine, intismeran autogene. The stock hit a 52-week high of $192.31 on Wednesday and closed at $194.82 on Thursday.

**Q: What is intismeran autogene?**

A: It’s Moderna’s personalized cancer vaccine, developed in partnership with Merck. It’s engineered to flag dozens of mutations unique to each patient’s tumor. The vaccine is custom-made for each individual based on their cancer’s genetic profile.

**Q: How did the cancer vaccine perform in clinical trials?**

A: In August 2026, Moderna and Merck announced that a Phase 3 trial showed the vaccine, combined with Merck’s Keytruda, prevented melanoma from returning more effectively than Keytruda alone. The trial involved approximately 1,100 patients. The stock nearly tripled on the news.

**Q: What’s next for Moderna’s cancer vaccine?**

A: Moderna will present full data at the European Society for Medical Oncology (ESMO) Congress in late October 2026. The company is also planning to file for regulatory approval. Beyond melanoma, the vaccine is being studied in lung cancer, bladder cancer, pancreatic cancer, and other tumor types.

**Q: Is Moderna still a Covid vaccine company?**

A: Yes and no. Covid vaccines remain a significant part of Moderna’s business — the company has five approved products, including Covid and RSV vaccines. But CEO Bancel says the company “has never been” just a Covid vaccine company. It’s an mRNA platform company using its technology across infectious diseases, oncology, rare diseases, and autoimmune conditions.

**Q: What does the analyst community think about Moderna stock?**

A: Analysts are divided. According to 23 analysts polled by S&P Global, the consensus rating is **Hold**, with an average price target of **$119.56** — implying about **38% downside** from current levels. However, several firms have raised their targets following the cancer vaccine data, with some now in the $150-$170 range.

**Q: Why is there such a big gap between the stock price and analyst targets?**

A: The stock has rallied dramatically — up over 500% year-to-date — on the strength of the cancer vaccine data. Many analysts have been slow to update their models to reflect the full potential of intismeran. Some remain skeptical that the market opportunity justifies the current valuation. Others are waiting for more data before adjusting their forecasts.

**Q: What are the risks for Moderna investors?**

A: Key risks include: (1) **Execution risk** on the personalized cancer vaccine — manufacturing and commercializing a custom therapy at scale is extremely difficult. (2) **Tumor type variability** — the melanoma data was strong, but the vaccine may not work as well in other cancers. (3) **Competition** — other companies are pursuing mRNA cancer vaccines, though BioNTech recently scrapped a trial for its own candidate. (4) **Valuation** — the stock has already priced in a lot of optimism.

**Q: What is Moderna’s financial position?**

A: Moderna reported a net loss of **$1.3 billion** in Q1 2026. The company has cash and investments of approximately **$7.5 billion** (as of March 2026) and recently raised **$2.6 billion through convertible notes**. Revenue for 2026 is projected to grow up to 10% from 2025 levels.

**Q: What other products does Moderna have in development?**

A: Beyond the cancer vaccine, Moderna is developing:

- **mRNA-1083**, a flu + Covid combination vaccine (under review in Europe and Canada)

- **mRNA-1403**, a norovirus vaccine (Phase 3 ongoing)

- **Propionic acidemia treatment**, with pivotal data expected by year-end

- **Multiple rare disease programs** targeting liver diseases

- **In vivo CAR-T** and other autoimmune disease programs

**Q: When is Moderna’s next earnings report?**

A: Moderna is expected to report Q3 2026 earnings on **Thursday, November 5, 2026**.

**Q: Should I buy Moderna stock now?**

A: This article is not financial advice. Whether to buy Moderna depends on your individual financial situation, risk tolerance, and investment thesis. The stock has already rallied dramatically, and analysts are divided on whether the current valuation is justified. Do your own research and consider consulting a financial advisor.

---

## Conclusion: A Company Transformed

Here’s what I keep coming back to when I think about Karen, the portfolio manager in Boston.

She spent years trying to convince people that Moderna was more than Covid. She had the science. She had the pipeline. She had the vision. But nobody wanted to listen.

Now they’re listening.

The stock is up **over 500% this year**. It hit a new 52-week high this week. And the catalyst that drove the rally — a personalized cancer vaccine that could change how we treat cancer — is just beginning to show what it can do.

CEO Stéphane Bancel’s message at the Bernstein conference was simple: **Moderna was never a Covid company**. It’s an mRNA platform company. And the platform is now delivering results across multiple therapeutic areas.

The next few months will be critical. The ESMO presentations in late October will provide the full data on intismeran. The company is preparing for regulatory filings. And pivotal data for its rare disease program is expected by year-end.

For investors, the question is whether the current valuation reflects reality or hype. Analysts are divided, with some seeing significant downside and others believing the rally is just getting started.

But for Karen, the debate is settled. She saw the science before the market did. And now the market is catching up.

Moderna isn’t just a Covid vaccine company anymore. It’s a cancer vaccine company. A rare disease company. A platform company.

And the market is finally starting to believe it.

---

## Disclaimer

**This article is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. The author has no position in Moderna (MRNA), Merck (MRK), or any related securities. Information presented here is based on publicly available sources and reported figures as of the publication date. Clinical trial results are not guarantees of future performance or regulatory approval. The stock market involves risk, including the potential loss of principal. Past performance does not guarantee future results. Always consult with a qualified financial advisor before making any investment decisions.**